NeRRe Therapeutics is a clinical-stage biopharma company based in Stevenage, UK, developing orvepitant, a once-daily neurokinin-1 (NK-1) receptor antagonist, as a first-in-class treatment for cough hypersensitivity disorders. The company has demonstrated proof of efficacy in patients with refractory or unexplained chronic cough. NeRRe is now advancing orvepitant into clinical development for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a severe progressive fibrotic lung disease in which cough is a dominant, disabling symptom. Preparations are underway to start a Phase 2 trial evaluating orvepitant in IPF-related chronic cough. The financing will primarily fund that Phase 2 clinical development. The company notes there are currently no approved treatments for chronic cough in IPF and that IPF is designated an orphan disease in Europe and the US. NeRRe Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of NK receptor antagonists. Its lead oral candidate is orvepitant, an NK-1 antagonist, and it also develops NT-814, a dual NK-1,3 antagonist. The company plans to use recent financing to generate Phase 2 data on orvepitant for a common chronic respiratory condition and to advance NT-814 into Phase 2 as a potential non-hormonal treatment for post-menopausal vasomotor symptoms. NeRRe was founded in 2012 as a spinout from GSK, which transferred its NK antagonist portfolio including clinical data, toxicity, safety and formulation packages and associated IP. The company is led by CEO Mary Kerr and CSO/COO Dr. Mike Trower and is based at the Stevenage Bioscience Catalyst in the UK. It remains clinical-stage while advancing its candidates toward mid-stage trials.

Total raised

$56M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2021